NIMHi016-A            
            
        General
| Cell Line | |
| hPSCreg name | NIMHi016-A | 
| Cite as: | NIMHi016-A (RRID:CVCL_E6X2) | 
| Cell line type | Human induced pluripotent stem cell (hiPSC) | 
| Similar lines | No similar lines found. | 
| Last update | 8th October 2024 | 
| User feedback | |
| Provider | |
| Generator | National Institute of Mental Health and Neurosciences (NIMH) | 
| External Databases | |
| BioSamples | SAMEA116131285 | 
| Cellosaurus | CVCL_E6X2 | 
| General Information | |
| Publications | |
| * Is the cell line readily obtainable for third parties? | No | 
Donor Information
| General Donor Information | |
| Sex | male | 
| Phenotype and Disease related information (Donor) | |
| Diseases | A disease was diagnosed. | 
| External Databases (Donor) | |
| BioSamples | SAMEA116131286 | 
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes | 
| Was the consent voluntarily given? | Yes | 
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes | 
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes | 
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes | 
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised | 
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes | 
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No | 
| How may genetic information associated with the cell line be accessed? | Controlled Access | 
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No | 
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes | 
| Name of accrediting authority involved? | Institutional Ethics Committee (IEC), NIMHANS | 
| Approval number | |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | 
hIPSC Derivation
| General | |
| Source cell line name | Fibroblasts | 
| Source cell type | |
| Reprogramming method | |
| Vector type | Non-integrating | 
| Vector | Sendai virus | 
| Is reprogramming vector detectable? | Yes | 
| Methods used | 
	PCR	 | 
| Vector free reprogramming | |
| Other | |
| Derived under xeno-free conditions | Unknown | 
| Derived under GMP? | Yes | 
| Available as clinical grade? | Unknown | 
Culture Conditions
| Surface coating | Vitronectin | ||||||
| Feeder cells | No | ||||||
| Passage method | Enzyme-free cell dissociation 
											EDTA										 | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium | Essential 8™ Supplements 
 | ||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No | ||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No | ||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No | 
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles | 
| SSEA-4 | Yes |  | ||||
| POU5F1 (OCT-4) | Yes |  | ||||
| TRA 1-60 | Yes |  | 
Differentiation Potency
Genotyping
| Karyotyping (Cell Line) | |
| Has the cell line karyotype been analysed? | Yes | 
| Other Genotyping (Cell Line) | |

Login to share your feedback, experiences or results with the research community.